HUP0203466A3 - Synergic combination of an nk1 receptor antagonist and a gaba structural analog and pharmaceutical composition containing it and use thereof - Google Patents

Synergic combination of an nk1 receptor antagonist and a gaba structural analog and pharmaceutical composition containing it and use thereof

Info

Publication number
HUP0203466A3
HUP0203466A3 HU0203466A HUP0203466A HUP0203466A3 HU P0203466 A3 HUP0203466 A3 HU P0203466A3 HU 0203466 A HU0203466 A HU 0203466A HU P0203466 A HUP0203466 A HU P0203466A HU P0203466 A3 HUP0203466 A3 HU P0203466A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
receptor antagonist
structural analog
synergic combination
Prior art date
Application number
HU0203466A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0203466A2 publication Critical patent/HUP0203466A2/hu
Publication of HUP0203466A3 publication Critical patent/HUP0203466A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0203466A 1999-10-07 2000-10-05 Synergic combination of an nk1 receptor antagonist and a gaba structural analog and pharmaceutical composition containing it and use thereof HUP0203466A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (2)

Publication Number Publication Date
HUP0203466A2 HUP0203466A2 (hu) 2003-02-28
HUP0203466A3 true HUP0203466A3 (en) 2005-03-29

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203466A HUP0203466A3 (en) 1999-10-07 2000-10-05 Synergic combination of an nk1 receptor antagonist and a gaba structural analog and pharmaceutical composition containing it and use thereof

Country Status (38)

Country Link
EP (2) EP1221950B1 (hu)
JP (2) JP2003510356A (hu)
KR (1) KR20020060192A (hu)
CN (1) CN1387434A (hu)
AP (1) AP2002002501A0 (hu)
AR (1) AR029646A1 (hu)
AT (1) ATE269072T1 (hu)
AU (2) AU7663300A (hu)
BG (1) BG106548A (hu)
BR (1) BR0014598A (hu)
CA (1) CA2385930A1 (hu)
CO (1) CO5280195A1 (hu)
CR (1) CR6614A (hu)
CZ (1) CZ20021116A3 (hu)
DE (1) DE60011650T2 (hu)
DK (1) DK1221950T3 (hu)
EA (1) EA004266B1 (hu)
EE (1) EE200200185A (hu)
ES (1) ES2220542T3 (hu)
GT (1) GT200000166A (hu)
HR (1) HRP20020286A2 (hu)
HU (1) HUP0203466A3 (hu)
IL (1) IL148965A0 (hu)
IS (1) IS6318A (hu)
MA (1) MA26826A1 (hu)
MX (1) MXPA02003484A (hu)
NO (1) NO20021625L (hu)
NZ (1) NZ517949A (hu)
OA (1) OA12063A (hu)
PA (1) PA8504301A1 (hu)
PE (1) PE20010708A1 (hu)
PL (1) PL357498A1 (hu)
PT (1) PT1221950E (hu)
SK (1) SK4542002A3 (hu)
TR (1) TR200200913T2 (hu)
UY (1) UY26376A1 (hu)
WO (2) WO2001024792A1 (hu)
ZA (1) ZA200202675B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
AU2003267732A1 (en) * 2002-10-08 2004-05-04 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
EP3946260A1 (en) 2019-03-26 2022-02-09 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
WO1998015277A2 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
PT1221950E (pt) 2004-08-31
HRP20020286A2 (en) 2003-08-31
NO20021625D0 (no) 2002-04-05
OA12063A (en) 2006-05-03
EP1221950A1 (en) 2002-07-17
WO2001024792A9 (en) 2002-09-06
ZA200202675B (en) 2003-04-15
IS6318A (is) 2002-03-21
TR200200913T2 (tr) 2002-09-23
MA26826A1 (fr) 2004-12-20
EA200200303A1 (ru) 2002-08-29
PE20010708A1 (es) 2001-07-27
ATE269072T1 (de) 2004-07-15
CN1387434A (zh) 2002-12-25
SK4542002A3 (en) 2003-09-11
CO5280195A1 (es) 2003-05-30
JP2003510355A (ja) 2003-03-18
DE60011650T2 (de) 2005-07-14
DK1221950T3 (da) 2004-09-20
IL148965A0 (en) 2002-11-10
PA8504301A1 (es) 2002-08-26
CA2385930A1 (en) 2001-04-12
AP2002002501A0 (en) 2002-06-30
BR0014598A (pt) 2002-06-11
KR20020060192A (ko) 2002-07-16
EP1233766A1 (en) 2002-08-28
WO2001024791A1 (en) 2001-04-12
AU1696201A (en) 2001-05-10
UY26376A1 (es) 2000-12-29
MXPA02003484A (es) 2004-09-10
GT200000166A (es) 2002-03-30
EP1221950B1 (en) 2004-06-16
EA004266B1 (ru) 2004-02-26
NZ517949A (en) 2003-08-29
CZ20021116A3 (cs) 2003-05-14
EE200200185A (et) 2003-04-15
WO2001024792A1 (en) 2001-04-12
ES2220542T3 (es) 2004-12-16
DE60011650D1 (de) 2004-07-22
JP2003510356A (ja) 2003-03-18
HUP0203466A2 (hu) 2003-02-28
CR6614A (es) 2003-12-04
BG106548A (en) 2002-12-29
NO20021625L (no) 2002-04-05
AR029646A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
HUP0004556A3 (en) Tetrazole-containing rapamycin analogs and their use for preparation of pharmaceutical compositions
HUP0203466A3 (en) Synergic combination of an nk1 receptor antagonist and a gaba structural analog and pharmaceutical composition containing it and use thereof
EG23759A (en) Stable extended release oral dosage composition
IL131818A0 (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative its salts and their solvates
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
HUP0202495A3 (en) Stable medicinal compositions for oral use
HUP0102658A3 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
HK1090840A1 (en) Extended release oral dosage composition
HUP0202500A3 (en) Use of a pharmaceutical combination of ethinylestradiol and drospirenone for producing pharmaceutical compositions having contraceptive activity
HUP0100626A3 (en) Kappa receptor opioid tetra peptides and pharmaceutical compositions comprising thereof
HUP0101437A3 (en) Oral pharmaceutical extended release dosage form
HUP0200111A3 (en) Use of essential fatty acids for preparation of pharmaceutical composition available in the prevention of cardiovascular events
HUP0204340A3 (en) Compositions for delivery of a cortisol antagonist and their use
HUP0004008A3 (en) Polymorphic form of a morpholine derivative having tachykinin receptor antagonist activity and pharmaceutical compositions containing the same
IL151369A0 (en) USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
IL144413A0 (en) Pharmaceutical compositions comprising a tnf antagonist
IL200482A0 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
HU9503624D0 (en) Use of p antagonist in pharmaceutical compositions
IL145188A0 (en) Processes for making pharmaceutical oral ecb formulations and compositions
IL159040A0 (en) A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
HUP0200707A3 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists pharmaceutical compositions containing them and their use
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
IL132986A0 (en) Rapamycin formulation for oral administration
IL141899A0 (en) Pharmaceutical compositions comprising a chemokine receptor antagonist and a cyclosporin
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions